Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications
Reviews in Cardiovascular Medicine · 05.03.2024 · 25 (3)
DOI: 10.31083/j.rcm2503087 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 05.03.2024. Verfasst von Orly Leiva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Advances in cancer therapies have improved oncologic outcomes but can potentially expose patients to risk of cardiovascular toxicity. While left ventricular (LV) dysfunction is a well-known cardiotoxicity of cancer therapy. Pulmonary hypertension (PH) and right ventricular (RV) dysfunction are seen with several cancer therapies, including alkylating agents, tyrosine kinase inhibitors (TKIs), and immunotherapy, and are associated with significant morbidity and mortality. Awareness and recognition of cancer therapy-associated PH and RV dysfunction is critical to identify underlying etiologies and institute the appropriate therapy. However, gaps exist in the current literature on the epidemiology of PH and RV dysfunction in cancer, underlying pathophysiology and optimal management strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.
- Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.
- Department of Medicine, New York University Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
- Cardio-Oncology Program, Heart, Vascular and Thoracic Institute, Cleveland Clinic Abu Dhabi, 00000 Abu Dhabi, United Arab Emirates.
- UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
Zitieren
APA
Leiva, O., Beaty, W., Soo, S., Agarwal, M. A., & Yang, E. H. (2024). Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications. Reviews in Cardiovascular Medicine, 25(3). https://doi.org/10.31083/j.rcm2503087
Vancouver
Leiva O, Beaty W, Soo S, Agarwal MA, Yang EH. Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications. Reviews in Cardiovascular Medicine. 2024;25(3). doi:10.31083/j.rcm2503087
BibTeX
@article{Leiva2024,
author = {Leiva, Orly and Beaty, William and Soo, Steven and Agarwal, Manyoo A and Yang, Eric H},
title = {Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications},
journal = {Reviews in Cardiovascular Medicine},
year = {2024},
volume = {25},
number = {3},
doi = {10.31083/j.rcm2503087}
}
EUVIMED